search
Back to results

Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study (FAPIC-QE)

Primary Purpose

Sepsis, Septic Shock, Bacteremia

Status
Completed
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
PathoRobot/ Patho-Doc Test result
Sponsored by
Hasselt University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Sepsis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Suspicion of sepsis
  • The drawning of blood cultures
  • Age >18 years

Exclusion Criteria:

  • Children (<18 years)
  • Patients who are not hospitalized and sent home after ED admission
  • Duplicate blood cultures from the same bacteraemia episode (7days between positives with the same organism, or 24h for different organisms)
  • Patients from who blood cultures are drawn on Friday evening (17h) or Saturday during intervention periods

Sites / Locations

  • Jessa Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

New diagnostic results NOT available

New diagnostic results available

Arm Description

Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. However, results will not be communicated. Only the results of routine blood cultures will be availabtle to the treating physician. No intervention will take place, care is provided according to normal routine practices.

Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. Results will be communicated via telephone by the consultant microbiologist and the electronic medical file to the treating physician. Results of routine blood cultures will also be available for all patients. Results of the new diagnostics are expected earlier, and the treating physician is able to make an earlier decision in terms of antibiotic therapy if he/she deems it necessary.

Outcomes

Primary Outcome Measures

Median time from specimen collection/arrival in the laboratory until antibiotic regimen change
Time period between collection of blood cultures until the first change in antibiotic regimen

Secondary Outcome Measures

Median time to appropriate, species-specific antibiotic therapy
Time period between collection of blood cultures until the first administration of species-specific antibiotic therapy
In-hospital mortality
In-hospital mortality
Time to organism identification
Time period between collection of blood cultures until the time to identification of a causative organism with the new diagnostics and with blood cultures
Time to effective therapy
Time period between collection of blood cultures until the first administration of antibiotic therapy effective againts the causative organism
Time to optimal therapy
Time period between collection of blood cultures until the first administration of antibiotic therapy that is optimal for patient recovery
30-day all cause mortality
Number of patients with 30-day all cause mortality
Length-of-stay
Length of hospital stay
Length of ICU stay
Length of stay in an Intensive Care Unit
Destination at Discharge
Destination after discharge (home, rehabilitation home, nursing home, ...)

Full Information

First Posted
July 12, 2019
Last Updated
October 16, 2020
Sponsor
Hasselt University
Collaborators
Jessa Hospital, School of Medicine, University of Zagreb, Molzym, AIT Austrian Institute of Technology GmbH, BEE Robotics, University of Warwick, Claude Bernard University, Axo Science
search

1. Study Identification

Unique Protocol Identification Number
NCT04103203
Brief Title
Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study
Acronym
FAPIC-QE
Official Title
Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study
Study Type
Interventional

2. Study Status

Record Verification Date
October 2020
Overall Recruitment Status
Completed
Study Start Date
July 1, 2019 (Actual)
Primary Completion Date
April 30, 2020 (Actual)
Study Completion Date
April 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hasselt University
Collaborators
Jessa Hospital, School of Medicine, University of Zagreb, Molzym, AIT Austrian Institute of Technology GmbH, BEE Robotics, University of Warwick, Claude Bernard University, Axo Science

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The performance and clinical impact of two diagnostic systems will be evaluated using whole blood samples that are collected in parallel with samples for blood culture. As the rapid diagnostic systems will have the largest impact on severely ill patients (in need of a fast diagnosis) with bacterial infection, the evaluation will be performed in patients suspected of bacteraemia. During the study the new systems will be used in parallel with routine blood cultures. In alternating periods of 1 month, the results of the diagnostic system will be communicated to treating physicians (intervention) or not revealed (control). Blood culture results will be reported throughout the complete study period. Patients with suspected sepsis at the Emergency Department (ED), the department of infectious diseases/nephrology, and the department of haemodialysis will be included. In routine care, two blood culture sets (2x2 bottles) per patient are collected. One extra blood sample (EDTA tube, 9 ml of blood) will be sampled for each routine set of blood cultures. In addition, the clinical data of the patients will be collected. The samples will be sent to the clinical laboratory where samples are tested with the new systems during regular working hours in batches of 8 samples per run (2-3 runs per day). On average, 10%-20% of the blood cultures drawn on the presumption of bacteraemia yield bacterial pathogens. Previous data show that 13% of patients yield positive blood cultures. Thus, in order to collect blood samples of 100 new episodes of bacteraemia approximately 1000 patients (2000 blood cultures + 1000 EDTA tubes) have to be collected for each system (2000 patients in total). The results of the systems will be used to evaluate the clinical utility of the system regarding time to antibiotic treatment change and bacteraemia management. The system will be used directly for the diagnosis of patients, resulting in a possible change of treatment strategy. However, routine blood culture practices will still be done during the whole study period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sepsis, Septic Shock, Bacteremia

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Quasi-experimental intervention
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1978 (Actual)

8. Arms, Groups, and Interventions

Arm Title
New diagnostic results NOT available
Arm Type
No Intervention
Arm Description
Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. However, results will not be communicated. Only the results of routine blood cultures will be availabtle to the treating physician. No intervention will take place, care is provided according to normal routine practices.
Arm Title
New diagnostic results available
Arm Type
Experimental
Arm Description
Patients with suspected sepsis are included. Blood samples will be collected and analysed with the new diagnostics. Results will be communicated via telephone by the consultant microbiologist and the electronic medical file to the treating physician. Results of routine blood cultures will also be available for all patients. Results of the new diagnostics are expected earlier, and the treating physician is able to make an earlier decision in terms of antibiotic therapy if he/she deems it necessary.
Intervention Type
Diagnostic Test
Intervention Name(s)
PathoRobot/ Patho-Doc Test result
Intervention Description
Test results of the new diagnostics will be available to the treating physician.
Primary Outcome Measure Information:
Title
Median time from specimen collection/arrival in the laboratory until antibiotic regimen change
Description
Time period between collection of blood cultures until the first change in antibiotic regimen
Time Frame
at study completion, 10 months
Secondary Outcome Measure Information:
Title
Median time to appropriate, species-specific antibiotic therapy
Description
Time period between collection of blood cultures until the first administration of species-specific antibiotic therapy
Time Frame
at study completion, 10 months
Title
In-hospital mortality
Description
In-hospital mortality
Time Frame
at study completion, 10 months
Title
Time to organism identification
Description
Time period between collection of blood cultures until the time to identification of a causative organism with the new diagnostics and with blood cultures
Time Frame
at study completion, 10 months
Title
Time to effective therapy
Description
Time period between collection of blood cultures until the first administration of antibiotic therapy effective againts the causative organism
Time Frame
at study completion, 10 months
Title
Time to optimal therapy
Description
Time period between collection of blood cultures until the first administration of antibiotic therapy that is optimal for patient recovery
Time Frame
at study completion, 10 months
Title
30-day all cause mortality
Description
Number of patients with 30-day all cause mortality
Time Frame
at study completion, 10 months
Title
Length-of-stay
Description
Length of hospital stay
Time Frame
at study completion, 10 months
Title
Length of ICU stay
Description
Length of stay in an Intensive Care Unit
Time Frame
at study completion, 10 months
Title
Destination at Discharge
Description
Destination after discharge (home, rehabilitation home, nursing home, ...)
Time Frame
at study completion, 10 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Suspicion of sepsis The drawning of blood cultures Age >18 years Exclusion Criteria: Children (<18 years) Patients who are not hospitalized and sent home after ED admission Duplicate blood cultures from the same bacteraemia episode (7days between positives with the same organism, or 24h for different organisms) Patients from who blood cultures are drawn on Friday evening (17h) or Saturday during intervention periods
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Inge C Gyssens, MD, PhD
Organizational Affiliation
Hasselt University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Jessa Hospital
City
Hasselt
State/Province
Limburg
ZIP/Postal Code
3500
Country
Belgium

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26903338
Citation
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10. doi: 10.1001/jama.2016.0287.
Results Reference
background
PubMed Identifier
26903336
Citation
Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, Angus DC, Rubenfeld GD, Singer M; Sepsis Definitions Task Force. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):775-87. doi: 10.1001/jama.2016.0289.
Results Reference
background
PubMed Identifier
28101605
Citation
Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, Rochwerg B, Rubenfeld GD, Angus DC, Annane D, Beale RJ, Bellinghan GJ, Bernard GR, Chiche JD, Coopersmith C, De Backer DP, French CJ, Fujishima S, Gerlach H, Hidalgo JL, Hollenberg SM, Jones AE, Karnad DR, Kleinpell RM, Koh Y, Lisboa TC, Machado FR, Marini JJ, Marshall JC, Mazuski JE, McIntyre LA, McLean AS, Mehta S, Moreno RP, Myburgh J, Navalesi P, Nishida O, Osborn TM, Perner A, Plunkett CM, Ranieri M, Schorr CA, Seckel MA, Seymour CW, Shieh L, Shukri KA, Simpson SQ, Singer M, Thompson BT, Townsend SR, Van der Poll T, Vincent JL, Wiersinga WJ, Zimmerman JL, Dellinger RP. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017 Mar;43(3):304-377. doi: 10.1007/s00134-017-4683-6. Epub 2017 Jan 18.
Results Reference
background

Learn more about this trial

Fast Assay for Pathogen Identification - Quasi-Experimental Intervention Study

We'll reach out to this number within 24 hrs